Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review

Keyphrases

• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 100%
• HIV Patients 100%
• Clinical Characteristics 100%
• Pembrolizumab 100%
• Clinical Outcomes 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 40%
• Patients with Prostate Cancer 40%
• Disease Progression 20%
• Docetaxel 20%
• Clinical Trials 20%
• Effective Treatment 20%
• Prostate Cancer 20%
• Patient Demographics 20%
• Treatment Options 20%
• Targeted Therapy 20%
• HIV Infection 20%
• Duration of Response 20%
• Response to Treatment 20%
• Single Institution 20%
• Radiological Response 20%
• Highly Active Antiretroviral Therapy (HAART) 20%
• Safe Treatment 20%
• Clinical History 20%
• Biochemical Response 20%
• Immune-related Adverse Events 20%
• Retrospective Case 20%

Medicine and Dentistry

• Prostate Cancer 100%
• Human Immunodeficiency Virus 100%
• Immunotherapy 100%
• Pembrolizumab 62%
• Human Immunodeficiency Virus Infection 12%
• Clinical Trial 12%
• Disease Exacerbation 12%
• Targeted Therapy 12%
• Highly Active Antiretroviral Therapy 12%
• Immune-Related Adverse Events 12%
• Docetaxel 12%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Prostate Cancer 100%
• Immunotherapy 100%
• Pembrolizumab 62%
• Clinical Trial 12%
• Docetaxel 12%
• Disease Exacerbation 12%
• Adverse Event 12%
• Human Immunodeficiency Virus Infection 12%